Retrospective study of all deaths among people undergoing naltrexone treatment for opioid dependence retrieved from the National Coronial Information System, 2000-2017.
Retaining patients in buprenorphine treatment is essential in maximising treatment outcomes and minimising mortality risk. Delivery of treatment via novel depot buprenorphine products has the potential to enhance patient adherence and retention in treatment.
This PhD project will examine untreated remission from alcohol problems. This will involve understanding the way in which those with alcohol problems engage in ‘spontaneous remission’ or ‘natural recovery’ outside the treatment setting.
This project will use linked administrative data to understand risk for mortality and other adverse outcomes during and after opioid agonist treatment (OAT). It will use standard biostatistical approaches and sophisticated machine learning techniques.
This project attempts to understand the global epidemiology of infectious disease among prisoners in all countries.
Alcohol and other drug (AOD) treatment is key for improving health and reducing the social impact of AOD use. However, the treatment itself is not the only variable that impacts on whether health outcomes are improved.
Smoking is a leading cause of preventable disease and death.
This project seeks to develop knowledge about effective models of partnership between rural Aboriginal communities and researchers across a range of community-led programs delivered from 2012-2016, which aimed to reduce drug and alcohol-related harm.
Substance use among pregnant women is a significant public health issue. A range of adverse effects have been noted including increased risk of miscarriage and still birth, reduction in fetal growth, birth defects, developmental delay, growth retardation and neurological abnormalities.
